OptiBiotix Health PLC Investor update
24 February 2021 - 06:00PM
RNS Non-Regulatory
TIDMOPTI
OptiBiotix Health PLC
24 February 2021
OptiBiotix Health plc
("OptiBiotix")
Investor update
OptiBiotix Health plc (AIM: OPTI), a life sciences busi ness d
eveloping compou n ds to tackle obesity, cardiovascular disease and
diabetes, a nnounces that Stephen O'Hara, CEO of OptiBiotix will
provide a live presentation to investors via the Investor Meet
Company platform on Tuesday, 2 March 2021 at 2pm GMT.
The presentation is open to all existing and potential
shareholders. Questions can be submitted pre-event via the Investor
Meet Company dashboard up until 9am the day before the meeting or
at any time during the live presentation. Investors can sign up to
Investor Meet Company for free and add to meet OptiBiotix.
To register for the presentation, please use this link:
https://www.investormeetcompany.com/optibiotix-health-plc/register-investor
Investors who already follow OptiBiotix on the Investor Meet
Company platform will automatically be invited.
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Neil Davidson, Chairman Contact via Walbrook below
Stephen O'Hara, Chief Executive
Cenkos Securities plc (Broker) Tel: 020 7397 8900
Callum Davidson / Neil McDonald
Michael Johnson / Russell Kerr (Sales)
Walbrook PR Ltd Mob: 07876 741 001
Anna Dunphy
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March
2012, brings science to the development of compounds which modify
the human microbiome - the collective genome of the microbes in the
body - in order to prevent and manage human disease and promote
wellness.
OptiBiotix has an extensive R&D programme working with
leading academics in the development of microbial strains,
compounds, and formulations which are used as active ingredients
and supplements. More than twenty international food and healthcare
supplement companies have signed agreements with OptiBiotix to
incorporate their human microbiome modulators into a wide range of
food products and drinks.
OptiBiotix is also developing its own range of consumer
supplements and health products. The Company's current areas of
focus include obesity, cardiovascular health, and diabetes.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRADKNBNABKDBBB
(END) Dow Jones Newswires
February 24, 2021 02:00 ET (07:00 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Feb 2024 to Mar 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Mar 2023 to Mar 2024